Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients
Summary
Third Opinion Trial Synopsis:
This is a study to find out if it is safe and helpful to give a combination of cells called CIML NK cells, a medicine called KP1237, and a small dose of IL-2 to people with a certain type of cancer called MM who have very little cancer left after their first treatment. They will give this combination before the patient gets a special type of transplant.
This is a study to find out if it is safe and helpful to give a combination of cells called CIML NK cells, a medicine called KP1237, and a small dose of IL-2 to people with a certain type of cancer called MM who have very little cancer left after their first treatment. They will give this combination before the patient gets a special type of transplant.
*Third Opinion AI Generated Synopsis
Trial Summary
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dose IL-2 in newly diagnosed MM patients who have minimal residual disease (MRD+) in first remission prior to autologous stem cell transplant (ASCT).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: